Cardiovascular Disease Cohort

Cognitive Dysfunction in Cardiovascular Patients Based on Resting fMRI

NCT05309824•Westlake University

Summary

The Cardiovascular Disease Cohort study is a prospective cohort study among cardiovascular disease patients enrolled in the Affiliated Hospital of Hangzhou Normal University. The primary aim of this study is to explore the brain mechanism of cognitive decline in cardiovascular disease patients using RS-FMRI and multi-omics techniques (including microbiome and metabolomics). Another aim of this study is to develop diagnosis and treatment strategies combining cardiovascular disease and cognitive function.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Atrial fibrillation patients
•* Age: 45-80 years old;
•* Consistent with the diagnosis of atrial fibrillation: standard 12-lead ECG recording or ≥30s single-lead ECG recording or 24-hour dynamic electrocardiogram, no obvious repeated P wave, irregular RR interval (when it does not damage atrioventricular conduction) can be diagnosed as clinical atrial fibrillation;
•* Anticoagulant therapy was selected according to cha2DS2-VASC score and HASBLED score;
•* Voluntarily participate in the study and sign the informed consent.
•* Age: 45-80 years old;
•* ECG diagnosis of left ventricular hypertrophy: increased QRS group voltage: CHEST lead Rv5 or Rv6\>2.5mV; Rv5+Sv1\>4.0mV (male) or \>3.5mV (female) Or in the limb lead, R1\>11.5 mV; RaVL \> 1.2 mV; RaVF \> 2.0 mV; RI + SIII \> 2.5 mV;
•* Sign informed consent to participate in the study voluntarily.
•* Age: 18-80 years;
•* Consistent with the diagnosis of pulmonary hypertension: at sea level and resting state, average pulmonary arterial pressure (mPAP) ≥25 mmHg (1mmHg=0.133kPa) measured by right heart catheter, or pulmonary arterial pressure ≥35 mmHg estimated by tricuspid regurgitation velocity indicated by cardiac ultrasound;
+7 more criteria

Exclusion Criteria

•* Valvular atrial fibrillation, atrial fibrillation caused by hyperthyroidism;
•* Severe liver and kidney failure;
•* Malignant tumor;
•* Diseases of the blood system;
•* History of major surgical trauma within six months.
•2. Left ventricular hypertrophy patients
•* Left ventricular hypertrophy caused by valvular heart disease and hyperthyroidism;
•* Severe liver and kidney failure;
•* Malignant tumor;
•* Diseases of the blood system;
+19 more criteria

Locations (1)

Westlake University

Hangzhou, Zhejiang, China

Key Dates

Start Date

April 1, 2022

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2027

Last Updated

June 13, 2025

Conditions

Cognitive DeclineCardiovascular Diseases

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITINGNA

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

NCT06909773

Cardiovascular Diseases

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cardiovascular Disease Cohort

Inclusion Criteria

Exclusion Criteria

Lombard Cohort of Brain Health Services

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

OPTImizing CArdiac REhabilitation by REfining Sleep and STress

CLEANer Aspiration for Pulmonary Embolism

The CACHE Study: Coronary Artery Care in HaEmophilia

Effects of Exergaming to Reduce Sedentary Time in Inactive Patients With Heart Failure